Bli medlem
Bli medlem

Du är här


BioStock: CombiGene paved the way for 2022 during 2020

On May 4, CombiGene's annual report was published, and the overall impression is that the company could turn the page to 2021 after covering a year of several advances. Not only has the company's preclinical program accelerated, but a production platform has also been established. The company also ticked off three new share issues, research grants from the EU and confirmations from regulatory authorities regarding how the company intends to carry out the final preclinical steps ahead of the first human studies scheduled to start next year.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision